A Phase II Randomized, Double-Blind, Placebo-Controlled Multi-Center Study to Assess the Safety, Tolerability, and Efficacy of Riociguat in Patients With Sickle Cell Diseases
Phase of Trial: Phase II
Latest Information Update: 23 Dec 2017
At a glance
- Drugs Riociguat (Primary)
- Indications Sickle cell anaemia
- Focus Adverse reactions
- 19 Apr 2017 Status changed from active, no longer recruiting to recruiting.
- 20 Sep 2016 Status changed from not yet recruiting to active, no longer recruiting.
- 23 Dec 2015 New trial record